Ascentage Pharma Group International (NASDAQ:AAPG) Coverage Initiated at B. Riley Financial

Research analysts at B. Riley Financial assumed coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research note issued on Wednesday. The brokerage set a “buy” rating and a $45.00 price target on the stock. B. Riley Financial’s price target would indicate a potential upside of 163.62% from the stock’s current price.

A number of other research firms also recently issued reports on AAPG. BTIG Research reissued a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Monday, April 13th. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Stock Down 0.3%

Shares of AAPG opened at $17.07 on Wednesday. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The firm has a fifty day simple moving average of $22.53 and a two-hundred day simple moving average of $24.99. Ascentage Pharma Group International has a 1-year low of $16.92 and a 1-year high of $48.45.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The business had revenue of $24.72 million for the quarter. On average, equities research analysts expect that Ascentage Pharma Group International will post -1.09 EPS for the current year.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several large investors have recently added to or reduced their stakes in the company. UBS Group AG lifted its holdings in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter. XY Capital Ltd boosted its holdings in Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after buying an additional 12,530 shares during the period. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International in the 2nd quarter worth $391,000. Citadel Advisors LLC bought a new position in Ascentage Pharma Group International in the 3rd quarter worth $383,000. Finally, ABC Arbitrage SA bought a new position in Ascentage Pharma Group International in the 3rd quarter worth $204,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.